Suberoylanilide Hydroxamic Acid Analogs with Heteroaryl Amide Group and Different Chain Length: Synthesis and Effect on Histone Deacetylase

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Jan 11

PMID 38202821

Authors

Gabriele Micheletti

Carla Boga

Giacomo Drius

Silvia Bordoni

Natalia Calonghi

Affiliations

Soon will be listed here.

Abstract

This review covers the last 25 years of the literature on analogs of suberoylanilide hydroxamic acid (SAHA, known also as vorinostat) acting as an HDAC inhibitor. In particular, the topic has been focused on the synthesis and biological activity of compounds where the phenyl group (the surface recognition moiety, CAP) of SAHA has been replaced by an azaheterocycle through a direct bond with amide nitrogen atom, and the methylene chain in the linker region is of variable length. Most of the compounds displayed good to excellent inhibitory activity against HDACs and in many cases showed antiproliferative activity against human cancer cell lines.

Citing Articles

Integrating a quinone substructure into histone deacetylase inhibitors to cope with Alzheimer's disease and cancer.

Guardigni M, Greco G, Poeta E, Santini A, Tassinari E, Bergamini C RSC Med Chem. 2024; 15(6):2045-2062.

PMID: 38911150 PMC: 11187553. DOI: 10.1039/d4md00175c.

References

Yang W, Li L, Ji X, Wu X, Su M, Sheng L . Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors. Bioorg Med Chem. 2014; 22(21):6146-55. DOI: 10.1016/j.bmc.2014.08.030. View

de Ruijter A, van Gennip A, Caron H, Kemp S, van Kuilenburg A . Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2002; 370(Pt 3):737-49. PMC: 1223209. DOI: 10.1042/BJ20021321. View

Finnin M, Donigian J, Cohen A, Richon V, Rifkind R, Marks P . Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999; 401(6749):188-93. DOI: 10.1038/43710. View

Jung M, Brosch G, Kolle D, Scherf H, Gerhauser C, Loidl P . Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem. 1999; 42(22):4669-79. DOI: 10.1021/jm991091h. View

Remiszewski S, Sambucetti L, Atadja P, Bair K, Cornell W, Green M . Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002; 45(4):753-7. DOI: 10.1021/jm015568c. View

Oanh D, Hai H, Park S, Kim H, Han B, Kim H . Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Bioorg Med Chem Lett. 2011; 21(24):7509-12. DOI: 10.1016/j.bmcl.2011.07.124. View

Kim H, Bae S . Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011; 3(2):166-79. PMC: 3056563. View

Dasko M, de Pascual-Teresa B, Ortin I, Ramos A . HDAC Inhibitors: Innovative Strategies for Their Design and Applications. Molecules. 2022; 27(3). PMC: 8837987. DOI: 10.3390/molecules27030715. View

Cai X, Zhai H, Wang J, Forrester J, Qu H, Yin L . Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem. 2010; 53(5):2000-9. DOI: 10.1021/jm901453q. View

10.

Ru J, Wang Y, Li Z, Wang J, Ren C, Zhang J . Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects. Eur J Med Chem. 2023; 261:115800. DOI: 10.1016/j.ejmech.2023.115800. View

11.

Mantzourani C, Gkikas D, Kokotos A, Nummela P, Theodoropoulou M, Wu K . Synthesis of benzoxazole-based vorinostat analogs and their antiproliferative activity. Bioorg Chem. 2021; 114:105132. DOI: 10.1016/j.bioorg.2021.105132. View

12.

Pardo-Jimenez V, Navarrete-Encina P, Diaz-Araya G . Synthesis and Biological Evaluation of Novel Thiazolyl-Coumarin Derivatives as Potent Histone Deacetylase Inhibitors with Antifibrotic Activity. Molecules. 2019; 24(4). PMC: 6412891. DOI: 10.3390/molecules24040739. View

13.

Guan P, Wang L, Hou X, Wan Y, Xu W, Tang W . Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif. Bioorg Med Chem. 2014; 22(21):5766-75. DOI: 10.1016/j.bmc.2014.09.039. View

14.

Nam N, Huong T, Dung D, Thi Phuong Dung P, Oanh D, Park S . Synthesis, bioevaluation and docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents. J Enzyme Inhib Med Chem. 2013; 29(5):611-8. DOI: 10.3109/14756366.2013.832238. View

15.

He B, Velaparthi S, Pieffet G, Pennington C, Mahesh A, Holzle D . Binding ensemble profiling with photoaffinity labeling (BEProFL) approach: mapping the binding poses of HDAC8 inhibitors. J Med Chem. 2009; 52(22):7003-13. PMC: 2789734. DOI: 10.1021/jm9005077. View

16.

Albrow V, Grimley R, Clulow J, Rose C, Sun J, Warmus J . Design and development of histone deacetylase (HDAC) chemical probes for cell-based profiling. Mol Biosyst. 2016; 12(6):1781-9. DOI: 10.1039/c6mb00109b. View

17.

Kozikowski A, Chen Y, Gaysin A, Savoy D, Billadeau D, Kim K . Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth. ChemMedChem. 2008; 3(3):487-501. PMC: 2692692. DOI: 10.1002/cmdc.200700314. View

18.

Vaidya A, Neelarapu R, Madriaga A, Bai H, Mendonca E, Abdelkarim H . Novel histone deacetylase 8 ligands without a zinc chelating group: exploring an 'upside-down' binding pose. Bioorg Med Chem Lett. 2012; 22(21):6621-7. PMC: 3472134. DOI: 10.1016/j.bmcl.2012.08.104. View

19.

Salmi-Smail C, Fabre A, Dequiedt F, Restouin A, Castellano R, Garbit S . Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. J Med Chem. 2010; 53(8):3038-47. DOI: 10.1021/jm901358y. View

20.

Mann B, Johnson J, Cohen M, Justice R, Pazdur R . FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007; 12(10):1247-52. DOI: 10.1634/theoncologist.12-10-1247. View